December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Impaired Endothelium-Dependent Vasodilatory Response in Diabetic Rats Is Ameliorated with Angiotensin Type 1 Receptor Blockade using Candesartan
Author Affiliations & Notes
  • N Horio
    Eye Research Joslin Diabetes Center Boston MA
  • AC Clermont
    Eye Research Joslin Diabetes Center Boston MA
  • BD Shoelson
    Eye Research Joslin Diabetes Center Boston MA
  • T Abiko
    Eye Research Joslin Diabetes Center Boston MA
  • EP Feener
    Eye Research Joslin Diabetes Center Boston MA
  • SE Bursell
    Eye Research Joslin Diabetes Center Boston MA
  • Footnotes
    Commercial Relationships   N. Horio, None; A.C. Clermont, None; B.D. Shoelson, None; T. Abiko, None; E.P. Feener, None; S.E. Bursell, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N Horio, AC Clermont, BD Shoelson, T Abiko, EP Feener, SE Bursell; Impaired Endothelium-Dependent Vasodilatory Response in Diabetic Rats Is Ameliorated with Angiotensin Type 1 Receptor Blockade using Candesartan . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Diabetes associated endothelial dysfunction plays an important role in progression of vascular complications, including diabetic retinopathy. Here, we first determined whether acetylcholine (ACh)-induced endothelium-dependent vasodilation is impaired in streptozotocin (STZ)-induced diabetic rats, and then investigated whether candesartan, an angiotensin type 1 (AT1) receptor blocker (ARB) can affect this endothelium-dependent vasodilatory response. Methods:Retinal blood flow (RBF) responses to intravitreally injected ACh (10-6 to 10-3 M) were measured with our video fluorescein angiography methodology in non-diabetic and diabetic rats. Diabetic rats after 1-week diabetes were treated with candesartan (10 µg/ml in drinking water) for a further 1-week period. Results:In non-diabetic rats, ACh induced a rapid, dose-dependent transient increase in RBF and retinal vessel diameters (maximal response 2 min after injection and a return to the baseline by 10 min). 10-4 M ACh induced the maximal RBF response (960.1±165.6 vs 589.6±135.3 pixel2/sec baseline, P<0.01). In diabetic rats, the ACh-induced RBF responses were significantly attenuated (P<0.05). Control diabetic rats in the candesartan treatment study showed comparable attenuated 10-5 M ACh-induced % changes in RBF response (11.5±24.5% diabetic vs 52.7±17.7% non-diabetic, P<0.01). Candesartan treated diabetic rats had an increased ACh-induced %RBF change (53.2±37.6%, P<0.05 compared with untreated diabetic rats), which was comparable to untreated non-diabetic rats. Vein diameters also showed vasodilation in treated diabetic rats (11.5±7.8% treatment vs 2.2±2.5% control, P<0.05). Conclusion:These findings provide the first demonstration of impaired retinal endothelium-dependent vasodilation in type 1diabetes. Inhibition of the renin-angiotensin system using an ARB ameliorates this retinal dysfunction in diabetes.

Keywords: 388 diabetic retinopathy • 305 acetylcholine 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×